

Tetrahedron Letters, Vol. 35, No. 29, pp. 5261-5262, 1994 Elsevier Science Ltd Printed in Great Britsin 0040-4039/94 \$7.00+0.00

0040-4039(94)01073-0


A First Selective Synthesis of Cyclopentaveratrylene

Hiroshi Hara,* Hiroshi Nakamura, Shin-ichi Watanabe and Osamu Hoshino*

Faculty of Pharamaceutical Sciences, Science University of Tokyo. Shinjuku-ku, Tokyo 162, Japan

Summary: A selective synthesis of cyclopentaveratrylene (2) starting from 3,4-bis(6-bromoveratryl)veratrole (6) or 3,4-diveratrylveratrole (7) is achieved.

A various type of Host compounds in Host-Guest chemistry, which develops extensively as a mimic model for enzymatic reactions,¹ have been synthesized. Among them, synthesis and characterization of calixarenes, one of cyclophanes, have been performed for investigation on the molecular recognition for the last decade,² whereas those of orthocyclophanes have not been done except for cyclotriveratrylene (1) derivatives.³ Recently, cyclopenta (2)- and cyclohexaveratrylenes (3) are formed as by-products⁴ along with 1 and cyclotetraveratrylene (4) in the reaction of veratryl alcohol with acid. However, a selective synthesis of 2 or 3 has been unsuccessful.⁵ In this report, we wish to describe a first selective synthesis of cyclopentaveratrylene (2).



We have recently⁸ reported that 5-silacyclotriveratrylenes (5) are synthesized from 3,4bis(6-bromoveratryl)veratrole (6).^{8,9} The findings suggested that 6 or its reduced compound $(7)^9$ might be a suitable starting material for a synthesis of 2. Thus, the dilithio compound (8),⁸ generated from 6, was allowed to react with 6-bromoveratraldehyde in THF at -50° C to give dibromo-dihydroxy linear pentamers (9)¹⁰ (amorphous mass; 59%) as a diastereomeric mixture. Deoxygenation (I2, PPh3,¹¹ PhH, reflux) of 9 gave the dibromopentamer $(10)^{10}$ (amorphous mass; 56%), which was also synthesized by acid treatment (trifluoroacetic acid, CH₂Cl₂, reflux) of 7 with 6-bromoveratryl alcohol (2 equiv.).

Cyclization¹² [n BuLi (2.5 eq.), THF, -50 °C; (EtO)₂CO (excess)] of 10 furnished 5oxocyclopentaveratrylene (11),¹⁰ mp 234-235 °C in 21% yield. Reduction (NaBH₄-AlCl₃.¹⁴ THF, reflux) of 11 produced cyclopentaveratrylene (2), mp 268-271 °C (lit.⁴ 268-270 °C), in 70% yield, ¹H-NMR spectral data of which were coincident with those reported in a literature.⁴

Thus, a first selective synthesis of cyclopentaveratrylene (2) was accomplished and application of this methodology to a selective synthesis of larger orthocyclophanes is in progress.

Acknowledgements: We thank Ms. N. Sawabe and Mrs. F. Hasegawa of this Faculty for ¹H-NMR and MS spectral measurements.

References and Notes

- 1. Seel, C.; Vögtle, F. Angew. Chem. Int. Ed. Engl. 1992, 31, 528 and references cited therein.
- 2. Gutsche, C. D. Acc. Chem. Res. 1983, 16, 161; Shinkai, S. Tetrahedron 1993, 49, 8933 and references cited therein.
- 3. Collet, A. Tetrahedron 1987, 43, 5725 and references cited therein.
- 4. Al-Farhan, E.; Keehn, P. M.; Stevenson, R. Tetrahedron Lett. 1992, 33, 3591.
- 5. A selective synthesis of cyclotetra-,⁶ cyclopenta-,⁶ and cycloheptabenzylenes⁷ has been reported.
- 6. Lee, W. Y.; Park, C. H.; Kim, Y. D. J. Org. Chem. 1992, 57, 4074.
- 7. Lee, W. Y.; Park, C. H.; Kim, H.-J.; Kim, S. J. J. Org. Chem. 1994, 59, 878.
- 8. Hara, H.; Satoh, H.; Hoshino, O. Heterocycles, 1992, 33, 43.
- 9. Umezawa, B.; Hoshino, O.; Hara, H.; Mitsubayashi, S. J. Chem. Soc. C, 1970, 465.
- 10. All new compounds were fully characterized by ¹H-NMR and HRMS.
- 11. Bohlmann, F.; Staffeldt, J.; Skuballa, W. Chem. Ber. 1976, 109, 1586.
- 12. Analogous reaction [ClCO₂Et or (EtO)₂CO] of 8 led to 5-oxocyclotriveratrylene¹³ (39 or 57%), reduction (NaBH₄-AlCl₃,¹⁴ THF, reflux) of which gave 1¹⁵ (62%).
- 13. Cookson, R. C.; Halton, B.; Stevens, I. D. R. J. Chem. Soc. B, 1968, 757.
- 14. Ono, A.; Suzuki, N.; Kamimura, J. Synthesis, 1987, 736.
- 15. Umezawa, B.; Hoshino, O.; Hara, H.; Ohyama, K.; Mitsubayashi, S.; Sakakibara, J. Chem. Pharm. Bull. 1969, 17, 2240.

5262

(Received in Japan 9 May 1994)